Biomarker value and pitfalls of serum S100B in the follow-up of high-risk melanoma patients
Standard
Biomarker value and pitfalls of serum S100B in the follow-up of high-risk melanoma patients. / Gebhardt, Christoffer; Lichtenberger, Ramtin; Utikal, Jochen.
In: J DTSCH DERMATOL GES, Vol. 14, No. 2, 02.2016, p. 158-64.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Biomarker value and pitfalls of serum S100B in the follow-up of high-risk melanoma patients
AU - Gebhardt, Christoffer
AU - Lichtenberger, Ramtin
AU - Utikal, Jochen
N1 - © 2016 Deutsche Dermatologische Gesellschaft (DDG). Published by John Wiley & Sons Ltd.
PY - 2016/2
Y1 - 2016/2
N2 - BACKGROUND AND OBJECTIVES: Serum levels of S100B are standard in monitoring advanced malignant melanoma patients in order to discriminate progressive from non-progressive disease. False-positive results lead to distress among patients and increase the amount of cost-intensive diagnostics. We therefore analyzed reported comorbid diseases as putative sources of excessive S100B release.PATIENTS AND METHODS: Here, we report a single-center experience on serum S100B levels in 2,664 blood samples from 1,113 stage IB to IV melanoma patients (AJCC) who presented for follow-up examinations over a period of 24 months.RESULTS: Overall, 295 (11%) of patients developed disease progression. In patients with a high tumor load, the rate of false-negative results was 30/185 (16%). The rate of false-positive results was 247/2369 (12%). One hundred and six false-positive results (69%) compared to 46 true-positive results (31%) were found in patients with cardiovascular diseases such as arrhythmia (50/32) or previous myocardial infarction (22/14). Moreover, obesity (85/14), liver cirrhosis (31/10), migraine (18/2), chronic kidney disease (13/2), and previous stroke (11/1) were found to be associated with false-positive S100B levels.CONCLUSIONS: Serum S100B is a useful quantitative biomarker in routine follow-up of high-risk melanoma patients. While false-negative results are frequent in patients with low tumor load, false-positive results are associated with several comorbid diseases and warrant careful reevaluation.
AB - BACKGROUND AND OBJECTIVES: Serum levels of S100B are standard in monitoring advanced malignant melanoma patients in order to discriminate progressive from non-progressive disease. False-positive results lead to distress among patients and increase the amount of cost-intensive diagnostics. We therefore analyzed reported comorbid diseases as putative sources of excessive S100B release.PATIENTS AND METHODS: Here, we report a single-center experience on serum S100B levels in 2,664 blood samples from 1,113 stage IB to IV melanoma patients (AJCC) who presented for follow-up examinations over a period of 24 months.RESULTS: Overall, 295 (11%) of patients developed disease progression. In patients with a high tumor load, the rate of false-negative results was 30/185 (16%). The rate of false-positive results was 247/2369 (12%). One hundred and six false-positive results (69%) compared to 46 true-positive results (31%) were found in patients with cardiovascular diseases such as arrhythmia (50/32) or previous myocardial infarction (22/14). Moreover, obesity (85/14), liver cirrhosis (31/10), migraine (18/2), chronic kidney disease (13/2), and previous stroke (11/1) were found to be associated with false-positive S100B levels.CONCLUSIONS: Serum S100B is a useful quantitative biomarker in routine follow-up of high-risk melanoma patients. While false-negative results are frequent in patients with low tumor load, false-positive results are associated with several comorbid diseases and warrant careful reevaluation.
KW - Adolescent
KW - Adult
KW - Aged
KW - Aged, 80 and over
KW - Biomarkers, Tumor
KW - Diagnostic Errors
KW - False Negative Reactions
KW - False Positive Reactions
KW - Female
KW - Germany
KW - Humans
KW - Longitudinal Studies
KW - Male
KW - Melanoma
KW - Middle Aged
KW - Neoplasm Proteins
KW - Prevalence
KW - Reproducibility of Results
KW - Risk Assessment
KW - S100 Calcium Binding Protein beta Subunit
KW - Sensitivity and Specificity
KW - Skin Neoplasms
KW - Young Adult
KW - Journal Article
KW - Research Support, Non-U.S. Gov't
U2 - 10.1111/ddg.12727
DO - 10.1111/ddg.12727
M3 - SCORING: Journal article
C2 - 26819111
VL - 14
SP - 158
EP - 164
JO - J DTSCH DERMATOL GES
JF - J DTSCH DERMATOL GES
SN - 1610-0379
IS - 2
ER -